Free Trial
NYSE:COR

Cencora (COR) Stock Price, News & Analysis

→ Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad)
Free COR Stock Alerts
$223.95
-0.79 (-0.35%)
(As of 05/3/2024 ET)
Compare
Today's Range
$222.20
▼
$224.86
50-Day Range
$224.00
▼
$245.77
52-Week Range
$163.37
▼
$246.75
Volume
2.22 million shs
Average Volume
1.29 million shs
Market Capitalization
$44.67 billion
P/E Ratio
24.50
Dividend Yield
0.91%
Price Target
$233.90
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Cencora MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
4.4% Upside
$233.90 Price Target
Short Interest
Bearish
4.73% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.31mentions of Cencora in the last 14 days
Based on 29 Articles This Week
Insider Trading
Selling Shares
$1.01 B Sold Last Quarter
Proj. Earnings Growth
9.36%
From $13.46 to $14.72 Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.46 out of 5 stars

Medical Sector

631st out of 5,424 stocks

Drugs, Proprietaries, & Sundries Industry

19th out of 42 stocks

See Top Rated MarketRank™ Stocks Here
COR stock logo

About Cencora Stock (NYSE:COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

COR Stock Price History

COR Stock News Headlines

April 29, 2024 | marketbeat.com
If This 1 Thing Changes, This 6.5% Dividend Will Be a Raging Buy
April 19, 2024 | insidertrades.com
Steven H. Collis Sells 10,754 Shares of Cencora, Inc. (NYSE:COR) Stock
May 4, 2024 | Porter & Company (Ad)
Elon to Transform U.S. Economy?
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
May 4, 2024 | americanbankingnews.com
Cencora, Inc. (NYSE:COR) to Post Q3 2024 Earnings of $3.26 Per Share, Leerink Partnrs Forecasts
May 4, 2024 | msn.com
Cencora (NYSE:COR) Q2 2024 Earnings Call Transcript
May 2, 2024 | seekingalpha.com
Cencora, Inc. (COR) Q2 2024 Earnings Call Transcript
May 2, 2024 | msn.com
COR Stock Earnings: Cencora Beats EPS, Misses Revenue for Q2 2024
May 2, 2024 | markets.businessinsider.com
Cencora Outperforms in Q2: A Buy Rating with Room to Grow
May 4, 2024 | Porter & Company (Ad)
Elon to Transform U.S. Economy?
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
May 2, 2024 | finance.yahoo.com
Cencora Second Quarter 2024 Earnings: Misses Expectations
May 2, 2024 | gurufocus.com
Q2 2024 Cencora Inc Earnings Call Transcript
May 1, 2024 | yahoo.com
Cencora misses revenue estimates on weight-loss drug shortage
May 1, 2024 | seekingalpha.com
Cencora, Inc. 2024 Q2 - Results - Earnings Call Presentation
May 1, 2024 | seekingalpha.com
Cencora Non-GAAP EPS of $3.80 beats by $0.11, revenue of $68.4B misses by $2.36B
May 1, 2024 | finance.yahoo.com
Cencora Inc (COR) Q2 Earnings: Adjusted EPS Exceeds Expectations, Raises Full-Year Guidance
May 1, 2024 | finance.yahoo.com
Cencora Reports Fiscal 2024 Second Quarter Results
May 1, 2024 | reuters.com
Cencora beats profit estimates on strong demand for costly specialty drugs
May 1, 2024 | americanbankingnews.com
Cencora (NYSE:COR) Given New $280.00 Price Target at Citigroup
April 26, 2024 | msn.com
Cencora (COR) to Report Q2 Earnings: What's in the Cards?
April 24, 2024 | americanbankingnews.com
Cencora (COR) to Release Quarterly Earnings on Wednesday
April 23, 2024 | investorplace.com
3 High-Quality Stocks That Will Never Put You in the Red
April 20, 2024 | finance.yahoo.com
Cencora, Inc. (COR)
April 19, 2024 | uk.investing.com
Cencora CEO Steven H. Collis sells shares worth over $2.5 million
April 18, 2024 | benzinga.com
At Cencora, Steven H Collis Chooses To Exercise Options, Resulting In $1.60M
April 18, 2024 | uk.finance.yahoo.com
Insider Sell: Cencora Inc (COR) Chairman, President & CEO Steven Collis Sells 10,754 Shares
April 18, 2024 | finance.yahoo.com
Executive Vice President & COO Robert Mauch Sells 57,564 Shares of Cencora Inc (COR)
April 17, 2024 | msn.com
Virginia receives over $100 million in opioid settlement payments
See More Headlines
Receive COR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/26 Dividend
2/08/2024
Dividend Payable
2/26/2024
Last Earnings
5/01/2024
Today
5/04/2024
Ex-Dividend for 5/24 Dividend
5/09/2024
Dividend Payable
5/24/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
9/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
Current Symbol
NYSE:COR
CUSIP
03073E10
CIK
1140859
Web
www.amerisourcebergen.com
Phone
(610) 727-7000
Fax
800-640-5221
Employees
46,000
Year Founded
2001

Price Target and Rating

Average Stock Price Target
$233.90
High Stock Price Target
$280.00
Low Stock Price Target
$190.00
Potential Upside/Downside
+4.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$9.14
Trailing P/E Ratio
24.50
Forward P/E Ratio
16.64
P/E Growth
1.69
Net Income
$1.75 billion
Net Margins
0.67%
Pretax Margin
0.83%
Return on Equity
268.67%
Return on Assets
4.13%

Debt

Debt-to-Equity Ratio
3.41
Current Ratio
0.89
Quick Ratio
0.52

Sales & Book Value

Annual Sales
$262.17 billion
Price / Sales
0.17
Cash Flow
$17.03 per share
Price / Cash Flow
13.15
Book Value
$6.15 per share
Price / Book
36.41

Miscellaneous

Outstanding Shares
199,480,000
Free Float
167,964,000
Market Cap
$44.67 billion
Optionable
Optionable
Beta
0.47

Social Links

Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Should I Buy Cencora Stock? COR Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Cencora, Inc.:

  • Cencora, Inc. has received a "Moderate Buy" recommendation from analysts, indicating positive sentiment towards the company's performance.
  • The average 1-year price target for Cencora, Inc. is $214.90, suggesting potential for growth in the stock price.
  • Recent insider activity includes major shareholder Walgreens Boots Alliance, Inc. selling shares at a higher price, indicating confidence in the company's future prospects.
  • Cencora, Inc. offers a diverse range of healthcare solutions and services, catering to various segments of the healthcare industry, which can lead to stable revenue streams.
  • The company's international presence in distributing pharmaceuticals and healthcare products provides opportunities for global expansion and revenue diversification.

Cons

Investors should be bearish about investing in Cencora, Inc. for these reasons:

  • Despite positive analyst ratings, there are concerns about potential market volatility affecting the stock price of Cencora, Inc.
  • Recent insider selling activities, such as EVP Elizabeth S. Campbell selling shares, may raise questions about the company's internal outlook.
  • Competition in the healthcare distribution industry is intense, which could impact Cencora, Inc.'s market share and profitability.
  • Regulatory changes in the pharmaceutical sector could pose challenges to Cencora, Inc.'s operations and financial performance.
  • Investors should carefully monitor the company's financial reports and industry trends to assess the long-term sustainability of Cencora, Inc.'s business model.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

COR Stock Analysis - Frequently Asked Questions

Should I buy or sell Cencora stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COR shares.
View COR analyst ratings or view top-rated stocks.

What is Cencora's stock price target for 2024?

10 Wall Street research analysts have issued 1-year target prices for Cencora's shares. Their COR share price targets range from $190.00 to $280.00. On average, they predict the company's share price to reach $233.90 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price.
View analysts price targets for COR or view top-rated stocks among Wall Street analysts.

How have COR shares performed in 2024?

Cencora's stock was trading at $205.38 at the beginning of the year. Since then, COR shares have increased by 9.0% and is now trading at $223.95.
View the best growth stocks for 2024 here.

When is Cencora's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our COR earnings forecast.

How were Cencora's earnings last quarter?

Cencora, Inc. (NYSE:COR) released its quarterly earnings data on Wednesday, May, 1st. The company reported $3.80 EPS for the quarter, beating analysts' consensus estimates of $3.65 by $0.15. The company had revenue of $68.41 billion for the quarter, compared to analysts' expectations of $70.60 billion. Cencora had a trailing twelve-month return on equity of 268.67% and a net margin of 0.67%. The business's revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $3.50 earnings per share.

How often does Cencora pay dividends? What is the dividend yield for Cencora?

Cencora announced a quarterly dividend on Thursday, May 2nd. Shareholders of record on Friday, May 10th will be paid a dividend of $0.51 per share on Friday, May 24th. This represents a $2.04 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Thursday, May 9th.
Read our dividend analysis for COR.

Is Cencora a good dividend stock?

Cencora (NYSE:COR) pays an annual dividend of $2.04 per share and currently has a dividend yield of 0.91%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 22.32%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, COR will have a dividend payout ratio of 13.86% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for COR.

What ETFs hold Cencora's stock?

ETFs with the largest weight of Cencora (NYSE:COR) stock in their portfolio include Burney U.S. Factor Rotation ETF (BRNY), VanEck Pharmaceutical ETF (PPH), AdvisorShares Focused Equity ETF (CWS), First Trust Consumer Staples AlphaDEX Fund (FXG), Strategas Macro Thematic Opportunities ETF (SAMT), BlackRock Future Health ETF (BMED), First Trust Dorsey Wright Momentum & Low Volatility ETF (DVOL) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What guidance has Cencora issued on next quarter's earnings?

Cencora updated its FY24 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of $13.30-13.50 for the period, compared to the consensus estimate of $13.45.

What is Paul E. Szurek's approval rating as Cencora's CEO?

27 employees have rated Cencora Chief Executive Officer Paul E. Szurek on Glassdoor.com. Paul E. Szurek has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Cencora own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cencora investors own include Digital Realty Trust (DLR), NVIDIA (NVDA), Cisco Systems (CSCO), AbbVie (ABBV), Crown Castle (CCI), AT&T (T), Intel (INTC), Realty Income (O), QUALCOMM (QCOM) and Enterprise Products Partners (EPD).

Who are Cencora's major shareholders?

Cencora's stock is owned by a variety of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (0.60%), Sumitomo Mitsui Trust Holdings Inc. (0.49%), Principal Financial Group Inc. (0.16%), Cornerstone Investment Partners LLC (0.15%), Wealth Enhancement Advisory Services LLC (0.14%) and Raymond James & Associates (0.14%). Insiders that own company stock include Elizabeth S Campbell, Gina Clark, Gina Clark, John G Chou, John G Chou, Lazarus Krikorian, Leslie E Donato, Leslie E Donato, Robert P Mauch, Robert P Mauch, Silvana Battaglia, Steven H Collis and Walgreens Boots Alliance, Inc.
View institutional ownership trends.

How do I buy shares of Cencora?

Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Cencora have any subsidiaries?
The following companies are subsidiares of Cencora: AB Singapore Investments Pte Ltd, AB UK Holdings Ltd, ASD Specialty Healthcare LLC, Access M.D., Alliance Healthcare, Amerisource Receivables Financial Corporation, AmerisourceBergen Drug Corporation, AmerisourceBergen Global Holdings GmbH, AmerisourceBergen Global Manufacturer Services GmbH, AmerisourceBergen Group GmbH, AmerisourceBergen International Holdings Inc., AmerisourceBergen Luxembourg S.a.r.L., AmerisourceBergen Services Corporation, AmerisourceBergen Sourcing LLC, AmerisourceBergen Specialty Group LLC, Anderson Packaging, AutoMed Technologies, BPL Group LLC, BPLH Ireland Unlimited Company, Bellco Health, Brecon Pharmaceuticals, Bridge Medical Inc, CD Smith Healthcare, H. D. Smith, IgG America, International Physician Networks L.L.C., IntrinsiQ, Lash Group, MWI Veterinary Supply, Network for Medical Communications & Research, PMSI, PharMEDium Healthcare, Pharmacy Healthcare Solutions, Premier Source, St. Francis Group, Trent Drug, US Bioservices, Wight Nederland Holdco 2 BV, World Courier, World Courier Group S.à r.l., and Xcenda.
Read More
This page (NYSE:COR) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners
Biden to Launch “FedNOW” [Move Your Money Now]
Priority Gold
Could Your Accounts Be Frozen?
Allegiance Gold
Automatic Income (from home)
Awesomely, LLC
Urgent Nvidia Warning
Altimetry
Global crypto currency reset (41 major banks signed up)
Stansberry Research
Jeff Bezos Just Humiliated Elon Musk
InvestorPlace
Forget Nvidia. This is the future of AI
Porter & Company
The asset beating inflation by 4x
Colonial Metals